HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
Haemonetics (HAE) shares rose, reaching multi-year highs, driven by BTIG's price target increase to $130 and positive retail sentiment. The brokerage expects expanded plasma business rollout to generate more revenue. HAE shares have gained 49% year-to-date. PCRX also saw gains. Arnab Paul has no position in the stocks mentioned.
How this was made
The 30-second read
Why it matters
The higher target may trigger short‑term buying pressure and lift sentiment toward the stock.
Market read
Analyst upgrade provides a fresh catalyst for HAE, potentially influencing short‑term price action.
What to watch
Potential regulatory hurdles or supply chain constraints could limit revenue upside.
Background
BTIG's upgrade follows Haemonetics' recent expansion of its plasma business.
Ticker impact
BTIG raised its price target on Haemonetics to $130 from $110, citing expected revenue boost from expanded plasma rollout.
likely upward pressure as investors price in higher target
Target raise reflects new revenue expectations; analysts often influence short‑term buying.
Market effects
Plasma collection and biotech services may see broader interest from analysts.
U.S. healthcare sector could benefit from perceived growth in Haemonetics.
Limited to investors tracking medical device and biotech stocks.
Counterpoint
Target raise may be premature if rollout costs exceed expectations.
Key entities
- CompanyHaemonetics
Medical device maker specializing in plasma collection.
- AnalystBTIG
Brokerage firm that issued the price target raise.
